Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine - Quiz - MDSpire

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

  • By

  • Caroline M Kopruszinski

  • John E Linley

  • Peter Thornton

  • Alison S Walker

  • Philip Newton

  • Sadhana Podichetty

  • Radhey Hemendra Ruparel

  • Luiz Henrique Moreira de Souza

  • Edita Navratilova

  • Guy Meno-Tetang

  • Ian Gurrell

  • David W Dodick

  • Claire Dobson

  • Tharani Chessell

  • Frank Porreca

  • Iain Chessell

  • February 28, 2025

  • 0 min

Share

Original Source(s)

Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

  • by Caroline M Kopruszinski, John E Linley, Peter Thornton, Alison S Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W Dodick, Claire Dobson, Tharani Chessell, Frank Porreca, Iain Chessell

  • February 28, 2025

Related Content

Premenstrual syndrome, premenstrual dysphoric disorder, and coping strategies in women with menstrual migraine

Zack Z. Ramilevich, M.D., Joins Marcus Neuroscience Institute as a General Neurologist

Board-certified neurologist Zack Z. Ramilevich, M.D., has joined Marcus Neuroscience Institute, part of Baptist Health, as a general neurologist.

  • by

  • March 26, 2026

  • 2 min
Systematic Review and Meta-Analysis of Peripheral Nerve Blocks for Treating Medication-Overuse Headache